Pegylated-interferon alfa-2a

DRUG4 trials

Sponsors

Hoffmann-La Roche, Bristol-Myers Squibb, Tanta University

Conditions

Chronic Hepatitis CHepatitis CHepatitis C, Chronic

Phase 2

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

CompletedNCT01012895

Bristol-Myers SquibbChronic Hepatitis C

Start: 2009-12-31End: 2014-02-28Updated: 2015-10-09

Phase 3

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

CompletedNCT00483938

Hoffmann-La RocheHepatitis C, Chronic

Start: 2007-06-30End: 2010-05-31Updated: 2017-01-23

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

CompletedNCT00800735

Hoffmann-La RocheHepatitis C, Chronic

Start: 2009-04-30End: 2012-03-31Updated: 2013-10-30

Phase 4

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

CompletedNCT02992457

Tanta UniversityHepatitis C

Start: 2015-01-31End: 2019-12-31Updated: 2023-08-25

Related Papers

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.

2020-04-305 citations

Efficacy and safety of sofosbuvir&ndash;ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Infection and Drug Resistance2018-02-2840 citations

Daclatasvir plus asunaprevir for <scp>HCV</scp> genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Liver International2015-12-1916 citations

Preliminary study of two antiviral agents for hepatitis C genotype 1.

2012-01-01449 citations